Treatment Options for Akathisia

First-line Approaches

The American Psychiatric Association recommends lowering the antipsychotic dosage, switching to another antipsychotic medication, or adding a beta-blocker such as propranolol as first-line treatments for patients with akathisia 1, 2
Reducing the dosage of the current antipsychotic while remaining within therapeutic range, or switching to an antipsychotic with lower akathisia risk, such as quetiapine or olanzapine, are recommended by the American College of Psychiatry 3, 1
The American College of Clinical Pharmacology advises against antipsychotic polypharmacy, which can increase side effect burden 4

Propranolol (10-30 mg two to three times daily) is the most consistently effective treatment for akathisia, according to the American Academy of Psychiatry and the Law 3
The American Academy of Child and Adolescent Psychiatry recommends monitoring for anticholinergic side effects when using anticholinergic agents 5

The American Academy of Pediatrics notes that akathisia can be misinterpreted as psychotic agitation or anxiety, leading to inappropriate increases in antipsychotic dosage that worsen the condition 6
For acute akathisia in emergency settings, intramuscular administration of medications is preferred over intravenous route, as recommended by the American Academy of Pediatrics 7, 8
The American Heart Association advises carefully considering the QT-prolonging effects of certain antipsychotics when switching medications in patients with high cardiovascular risk 7

The American Academy of Child and Adolescent Psychiatry suggests that benzodiazepines, such as clonazepam, can provide symptomatic relief and address the anxiety component of akathisia in patients who do not respond to first-line treatments, with moderate strength of evidence 9
The use of amantadine, an mild dopaminergic agent, is considered a fourth-line option for the treatment of akathisia, with limited evidence 9
Anticholinergic agents are notably less effective for akathisia compared to other extrapyramidal side effects, despite being commonly prescribed, according to the American Academy of Child and Adolescent Psychiatry 9

Children and adolescents may be at higher risk for extrapyramidal side effects, including akathisia, compared to adults, and should be monitored carefully for anticholinergic side effects when using anticholinergic agents, as recommended by the American Academy of Child and Adolescent Psychiatry 9

SSRI-induced akathisia is associated with increased suicidality, particularly with fluoxetine, and clinicians should systematically inquire about suicidal ideation before and after treatment initiation, according to the American Academy of Child and Adolescent Psychiatry 10
The American Academy of Child and Adolescent Psychiatry recommends being especially alert to the possibility of suicidality if SSRI treatment is associated with onset of akathisia 10

Akathisia is frequently misinterpreted as psychotic agitation or anxiety, leading clinicians to inappropriately increase antipsychotic doses, which worsens the condition, particularly in patients with a history of suicidal ideation, according to the American Academy of Child and Adolescent Psychiatry 11

Young age and male gender are risk factors for acute dystonic reactions, and children and adolescents have a higher risk for extrapyramidal side effects including akathisia compared to adults, as noted by the American Academy of Child and Adolescent Psychiatry 11
Benztropine 1-4 mg once or twice daily may be tried for akathisia, though not consistently helpful, and monitoring for anticholinergic side effects is essential, especially in children and adolescents, as reported by the American Academy of Child and Adolescent Psychiatry 11

Prophylactic antiparkinsonian agents may be considered in high-risk patients, particularly those with history of dystonic reactions or compliance concerns, and the need for antiparkinsonian agents should be reevaluated after the acute phase, as many patients no longer require them during long-term therapy, according to the American Academy of Child and Adolescent Psychiatry 11

The American Academy of Child and Adolescent Psychiatry suggests that short-term use of benzodiazepines, such as clonazepam, as adjuncts may help stabilize acutely agitated patients 12

Anticholinergic agents, such as benztropine, are less effective for akathisia compared to other extrapyramidal side effects, despite being commonly prescribed, according to the American Academy of Child and Adolescent Psychiatry 13
The American Academy of Child and Adolescent Psychiatry suggests that prophylactic antiparkinsonian agents should not be routinely prescribed, except in high-risk patients, such as those with a history of dystonic reactions or paranoid patients with compliance concerns 13
The American Academy of Child and Adolescent Psychiatry recommends reevaluating the need for antiparkinsonian agents after the acute phase, as many patients no longer require them during long-term therapy 13
Children and adolescents are at a higher risk for extrapyramidal side effects, including akathisia, compared to adults, and should be monitored carefully for anticholinergic side effects when using anticholinergic agents, according to the American Academy of Child and Adolescent Psychiatry 13

In adolescents receiving aripiprazole, reports of inner restlessness, inability to sit still, pacing, or a compulsion to move indicate akathisia rather than simple sedation. 14

Up to ≈ 50 % of youth on antipsychotic medication develop some form of movement disorder; therefore clinicians should document abnormal movements at baseline and repeat assessments every 3–6 months using the Abnormal Involuntary Movement Scale. 14, 15

When dose reduction and adjunctive measures fail or side effects remain intolerable, switching to an atypical antipsychotic with a lower akathisia risk—such as quetiapine or olanzapine—may improve tolerability in this population. 16

In patients who develop akathisia while on second‑generation antipsychotics, it is recommended to switch to an antipsychotic with a lower akathisia risk—specifically quetiapine or olanzapine (used with samidorphan or concurrent metformin to reduce weight gain). The switch should be carried out by gradual cross‑titration that considers each medication’s half‑life and receptor profile, thereby preserving therapeutic effect while minimizing akathisia recurrence 17